GlassScriptPrepare for your visit
Brian J Gillis
Colon & Rectal Surgery · Oakland, ME · NPI 1386711877
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$2,588.33
in general payments reported to CMS, 2019-2025 · $42.91 in 2025
The $42.91 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Who reported paying
General payments only, top 6 by amount.
- Takeda Pharmaceuticals U.S.A., INC. $1,129.43
- Abbvie INC. $524.15
- Allergan, INC. $407.97
- Salix Pharmaceuticals, A Division of Bausch Health US, LLC $298.92
- Exact Sciences Corporation $84.40
- Shire North American Group INC $37.64
Drugs and devices associated with these payments
Linzess Viberzi The Cologuard Plus Collection Kit Cologuard Collection Kit Xifaxan Creon
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Brian Gillis listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/17121/brian-j-gillis